AU2009232352B2 - Beta-turn peptidomimetic cyclic compounds for treating dry eye - Google Patents

Beta-turn peptidomimetic cyclic compounds for treating dry eye Download PDF

Info

Publication number
AU2009232352B2
AU2009232352B2 AU2009232352A AU2009232352A AU2009232352B2 AU 2009232352 B2 AU2009232352 B2 AU 2009232352B2 AU 2009232352 A AU2009232352 A AU 2009232352A AU 2009232352 A AU2009232352 A AU 2009232352A AU 2009232352 B2 AU2009232352 B2 AU 2009232352B2
Authority
AU
Australia
Prior art keywords
compound
day
scopolamine
dry eye
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009232352A
Other languages
English (en)
Other versions
AU2009232352A1 (en
Inventor
Garth Cumberlidge
Teresa Lama
Karen Meerovitch
H Uri Saragovi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mimetogen Pharmaceuticals Inc
Original Assignee
Mimetogen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mimetogen Pharmaceuticals Inc filed Critical Mimetogen Pharmaceuticals Inc
Publication of AU2009232352A1 publication Critical patent/AU2009232352A1/en
Application granted granted Critical
Publication of AU2009232352B2 publication Critical patent/AU2009232352B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12Cyclic peptides with only normal peptide bonds in the ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/123Tripeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2009232352A 2008-04-04 2009-04-03 Beta-turn peptidomimetic cyclic compounds for treating dry eye Active AU2009232352B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12303608P 2008-04-04 2008-04-04
US61/123,036 2008-04-04
US20887309P 2009-02-27 2009-02-27
US61/208,873 2009-02-27
PCT/US2009/002121 WO2009123761A1 (en) 2008-04-04 2009-04-03 Beta-turn peptidomimetic cyclic compounds for treating dry eye

Publications (2)

Publication Number Publication Date
AU2009232352A1 AU2009232352A1 (en) 2009-10-08
AU2009232352B2 true AU2009232352B2 (en) 2013-09-05

Family

ID=40897413

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009232352A Active AU2009232352B2 (en) 2008-04-04 2009-04-03 Beta-turn peptidomimetic cyclic compounds for treating dry eye

Country Status (9)

Country Link
US (4) US8293713B2 (enExample)
EP (1) EP2271337B1 (enExample)
JP (2) JP5480242B2 (enExample)
KR (1) KR101565185B1 (enExample)
CN (1) CN102046166B (enExample)
AU (1) AU2009232352B2 (enExample)
CA (1) CA2720141C (enExample)
ES (1) ES2521515T3 (enExample)
WO (1) WO2009123761A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102046166B (zh) 2008-04-04 2012-10-17 米梅托根药物公司 用于治疗干眼症的β-转角模拟肽环状化合物
JP6248103B2 (ja) * 2012-06-22 2017-12-13 ミメトゲン ファーマシュウティカルズ インコーポレイテッドMimetogen Pharmaceuticals, Inc. β−ターン環式ペプチド模倣化合物の合成
KR20150004652A (ko) 2013-07-03 2015-01-13 삼성디스플레이 주식회사 표시 패널, 이를 포함하는 표시 장치 및 이를 이용하는 영상 표시 방법
JP6267003B2 (ja) * 2014-02-27 2018-01-24 参天製薬株式会社 ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
EP3244851B1 (en) 2015-01-12 2024-10-16 Bausch + Lomb Ireland Limited Micro-droplet delivery device
KR20170135862A (ko) 2015-04-10 2017-12-08 켄달리온 테라퓨틱스 인코포레이티드 교체 가능한 앰플을 갖는 압전 디스펜서
CA2991661A1 (en) * 2015-07-09 2017-01-12 Mimetogen Pharmaceuticals, Inc. Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts
KR101718733B1 (ko) 2015-08-21 2017-03-22 국제약품 주식회사 레바미피드의 가용화 방법 및 이에 의해 제조된 안구건조증 치료용 액제
US10799447B2 (en) 2016-03-04 2020-10-13 James M. Rynerson Method of treating an eye disorder by inhibiting or disrupting bacterial biofilm formation
KR102412086B1 (ko) 2017-01-20 2022-06-22 켄달리온 테라퓨틱스 인코포레이티드 압전 유체 분배기
CN111712219A (zh) 2017-12-08 2020-09-25 科达莱昂治疗公司 流体递送对准系统
CN110092799B (zh) * 2018-01-29 2021-11-12 广州丹康医药生物有限公司 一种环状化合物、其制备方法和应用
US20190314198A1 (en) 2018-04-12 2019-10-17 Kedalion Therapeutics, Inc. Topical Ocular Delivery Methods and Devices for Use in the Same
US12350194B1 (en) 2018-04-12 2025-07-08 Bausch + Lomb Ireland Limited Topical ocular delivery of fluids with controlled mass dosing and wireless communication
EP3817696B8 (en) 2018-07-03 2024-12-11 Bausch + Lomb Ireland Limited Topical ocular delivery devices
US11679028B2 (en) 2019-03-06 2023-06-20 Novartis Ag Multi-dose ocular fluid delivery system
US12097145B2 (en) 2019-03-06 2024-09-24 Bausch + Lomb Ireland Limited Vented multi-dose ocular fluid delivery system
US11925577B2 (en) 2020-04-17 2024-03-12 Bausch + Lomb Ireland Limted Hydrodynamically actuated preservative free dispensing system
WO2021212038A1 (en) 2020-04-17 2021-10-21 Kedalion Therapeutics, Inc. Hydrodynamically actuated preservative free dispensing system having a collapsible liquid reservoir
US11938057B2 (en) 2020-04-17 2024-03-26 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
US12290472B2 (en) 2020-04-17 2025-05-06 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
JP2024520670A (ja) * 2021-06-02 2024-05-24 ザ テキサス エーアンドエム ユニヴァーシティ システム Trk受容体の選択的小分子アゴニスト及び部分アゴニスト
KR20240108412A (ko) * 2021-10-20 2024-07-09 스텔스 바이오테라퓨틱스 인코포레이티드 안과 병태를 치료하거나, 예방하거나, 억제하거나, 경감하거나 발병을 지연시키기 위한 방법 및 펩타이드 모방체를 포함하는 조성물
WO2023069255A1 (en) * 2021-10-20 2023-04-27 Stealth Biotherapeutics Inc. Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052843A1 (en) * 2000-01-18 2001-07-26 Mcgill University β-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS
EP1734052A1 (en) * 2005-06-13 2006-12-20 Primm S.R.L. Heterodimeric peptide compounds displaying ngf activity and their use to treat neurodegenerative disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8917217D0 (en) * 1989-07-27 1989-09-13 Smith & Nephew Ophthalmic compositions
US5545617A (en) * 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
CN1283997A (zh) * 1997-12-22 2001-02-14 人类基因组科学公司 角质形成细胞生长因子-2制剂
JP2001064198A (ja) * 1999-08-24 2001-03-13 Teika Seiyaku Kk 角膜疾患治療剤
EP1921087A1 (en) 2006-11-10 2008-05-14 Primm S.R.L. Process for the preparation of cyclic peptides
JP5576659B2 (ja) * 2006-12-05 2014-08-20 ザ ロイヤル インスティテューション フォー ジ アドバンスメント オブ ラーニング/ マギル ユニバーシティ Trkレセプター調節因子の使用方法
CN102046166B (zh) 2008-04-04 2012-10-17 米梅托根药物公司 用于治疗干眼症的β-转角模拟肽环状化合物
CA2752891C (en) * 2009-02-27 2018-08-21 Mimetogen Pharmaceuticals Inc. Peptidomimetic cyclic compounds for treating retinitis pigmentosa
JP6248103B2 (ja) * 2012-06-22 2017-12-13 ミメトゲン ファーマシュウティカルズ インコーポレイテッドMimetogen Pharmaceuticals, Inc. β−ターン環式ペプチド模倣化合物の合成

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052843A1 (en) * 2000-01-18 2001-07-26 Mcgill University β-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS
EP1734052A1 (en) * 2005-06-13 2006-12-20 Primm S.R.L. Heterodimeric peptide compounds displaying ngf activity and their use to treat neurodegenerative disorders

Also Published As

Publication number Publication date
US8293713B2 (en) 2012-10-23
CN102046166A (zh) 2011-05-04
CN102046166B (zh) 2012-10-17
US20110105410A1 (en) 2011-05-05
WO2009123761A1 (en) 2009-10-08
US8748391B2 (en) 2014-06-10
US9156882B2 (en) 2015-10-13
EP2271337A1 (en) 2011-01-12
EP2271337B1 (en) 2014-09-03
KR101565185B1 (ko) 2015-11-02
CA2720141A1 (en) 2009-10-08
AU2009232352A1 (en) 2009-10-08
HK1152898A1 (en) 2012-03-16
ES2521515T3 (es) 2014-11-12
US20140274910A1 (en) 2014-09-18
JP2011516477A (ja) 2011-05-26
JP2014080447A (ja) 2014-05-08
US20160082072A1 (en) 2016-03-24
JP5480242B2 (ja) 2014-04-23
KR20110010712A (ko) 2011-02-07
US20120322747A1 (en) 2012-12-20
CA2720141C (en) 2014-01-28
US9707267B2 (en) 2017-07-18
JP5870348B2 (ja) 2016-02-24

Similar Documents

Publication Publication Date Title
AU2009232352B2 (en) Beta-turn peptidomimetic cyclic compounds for treating dry eye
AU2010217889B2 (en) Peptidomimetic cyclic compounds for treating retinitis pigmentosa
US20240043396A1 (en) Methods of treating ocular fibrotic pathologies
HK1152898B (en) Beta-turn peptidomimetic cyclic compounds for treating dry eye
US20210228622A1 (en) Compositions of oxyhydrogen and the thereapeutic use thereof for ocular conditions
JP7749269B2 (ja) 新規のd-アミノ酸誘導体及びこれを含む薬学組成物
EP3284475B1 (en) Agent for prevention or treatment of corneal disorders
US20250161403A1 (en) Peptides and methods of use thereof in treating ocular disorders
US20250170143A1 (en) Methods of treating ocular fibrotic pathologies
EP2157082B1 (en) Neurite formation promoter
CN118434434A (zh) 用于治疗、预防、抑制、改善眼科病状或延缓其发作的方法和包括肽模拟物的组合物
HK1161980A (en) Peptidomimetic cyclic compounds for treating retinitis pigmentosa
JPH1180000A (ja) 翼状片予防・治療剤

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ LAMA, TERESA; CUMBERLIDGE, GARTH; MEEROVITCH, KAREN AND SARAGOVI, H URI

FGA Letters patent sealed or granted (standard patent)